title: Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
abstract: The many advantages of registered bioidentical sex hormones over registered, conventional, non-bioidentical menopausal hormone therapy (MHT) are considered. The transdermal route of estrogen administration avoids excess venous thromboembolic and ischemic stroke events. There is some indication that conjugated equine estrogens are more thrombogenic and most likely induce some hypertensive responses; estradiol might also be superior to conjugated equine estrogens (CEE) in terms of global cardiovascular health. The most valid evidence presently suggests that CEE-only treatment does not increase the risk of breast cancer and even may reduce it. But its combination with a synthetic progestogen (mainly medroxyprogesterone acetate) is a critical issue since it seems to be primarily associated with an increased incidence of breast cancer, however similar to or lower than that associated with some common lifestyle factors. Though not yet proven in a randomized, controlled trial, MHT continuously combining oral micronized progesterone with transdermal estradiol can presently be considered as the optimal MHT. It is not only safer than custom-compounded bioidentical hormones but also than oral conventional MHT and has the best breast profile; registered products for such optimal MHT are available around the world and must be preferred.
authors.affiliation: a Service de Gynécologie-Obstétrique , CHU Brugmann, Université Libre de Bruxelles , Bruxelles , Belgium.
authors.forename: M
authors.initials: M
authors.lastname: L'Hermite
mesh_terms: D000279:Administration, Cutaneous; D001943:Breast Neoplasms / Q000139:chemically induced; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage* / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D008593:Menopause / Q000187:drug effects / Q000502:physiology*; D057285:Precision Medicine; D011374:Progesterone / Q000008:administration & dosage* / Q000009:adverse effects; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D013045:Species Specificity; D020521:Stroke / Q000139:chemically induced; D054556:Venous Thromboembolism / Q000139:chemically induced
chemical_list: D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D011372:Progestins; D011374:Progesterone; D004958:Estradiol
keywords: Menopausal hormone therapy; breast cancer; cardiovascular events and mortality; ischemic stroke; natural progesterone; registered bioidentical hormones; thromboembolic events; transdermal estradiol